Hepatic toxicology following single and multiple exposure of engineered nanomaterials utilising a novel primary human 3D liver microtissue model

Particle and Fibre Toxicology

Volumn 11, Issue 1, 2014, Pages

  Kermanizadeh, Ali ^a,b   Løhr, Mille ^a   Roursgaard, Martin ^a   Messner, Simon ^a   Gunness, Patrina ^a   Kelm, Jens M ^a   Møller, Peter ^a   Stone, Vicki ^b   Loft, Steffen ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b HERIOT WATT UNIVERSITY   (United Kingdom)

Author keywords

3D human liver microtissue; Engineered nanomaterials; Genotoxicity; Inflammation; Lipid peroxidation

Indexed keywords

MULTI WALLED NANOTUBE; NANOMATERIAL; SILVER; SILVER NANOPARTICLE; TITANIUM DIOXIDE; ZINC OXIDE NANOPARTICLE; ALB PROTEIN, HUMAN; CARBON NANOTUBE; CYTOKINE; METAL NANOPARTICLE; SERUM ALBUMIN; TITANIUM; ZINC OXIDE;

ARTICLE; CYTOKINE RELEASE; CYTOTOXICITY; ENVIRONMENTAL EXPOSURE; GENOTOXICITY; LIPID PEROXIDATION; LIVER TOXICITY; LONG TERM EXPOSURE; MODEL; NANOTOXICOLOGY; PRIORITY JOURNAL; THREE DIMENSIONAL LIVER MICROTISSUE MODEL; AGONISTS; BIOSYNTHESIS; CELL CULTURE; CHEMISTRY; COCULTURE; COMPARATIVE STUDY; CYTOLOGY; DNA DAMAGE; DRUG EFFECTS; EVALUATION STUDY; HUMAN; IMMUNOLOGY; LIVER; LIVER CELL; METABOLISM; OXIDATIVE STRESS; PATHOLOGY; PROCEDURES; SECRETION (PROCESS); STROMA CELL; TOXIC HEPATITIS; TOXICITY TESTING; TRANSMISSION ELECTRON MICROSCOPY; ULTRASTRUCTURE;

CELLS, CULTURED; COCULTURE TECHNIQUES; CYTOKINES; DNA DAMAGE; DRUG-INDUCED LIVER INJURY; HEPATOCYTES; HUMANS; LIPID PEROXIDATION; LIVER; METAL NANOPARTICLES; MICROSCOPY, ELECTRON, TRANSMISSION; NANOSTRUCTURES; NANOTUBES, CARBON; OXIDATIVE STRESS; SERUM ALBUMIN; SILVER; STROMAL CELLS; TITANIUM; TOXICITY TESTS, ACUTE; ZINC OXIDE;

EID: 84964697470     PISSN: None     EISSN: 17438977     Source Type: Journal    
DOI: 10.1186/s12989-014-0056-2     Document Type: Article

References (58)

1. Maynard AD, Aitkin RJ, Butz T, Colvin V, Donaldson K, Oberdorster G, Philbert MA, Ryan J, Seaton A, Stone V, Tinkle S, Tran L, Walker NJ, Warheit DB: Safe handling of nanotechnology. Nature 2006, 444:267-269.
2. CPI home page [http://www.nanotechproject.org/cpi/]-accessed 12-06-2014.
3. Tetley TD: Health effects of nanomaterials. Bionanotechnology 2007, 35:527-531.
4. Hoet PHM, Hohlfeld IB, Salata O: Nanoparticles-known and unknown health risks. J Nanobiotechnology 2004, 2:12-27.
5. Johnston H, Brown D, Kermanizadeh A, Gubbins E, Stone V: Investigating the relationship between nanomaterial hazard and physicochemical properties: informing the exploitation of nanomaterials with therapeutic and diagnosis applications. J Control Release 2012, 164:307-313.
6. Oberdorster G, Maynard A, Donaldson K, Castronova V, Fitzpatrick J, Ausman K, Carter J, Karn B, Kreyling W, Lai D, Olin S, Monteiro-Riviere N, Warheit DB, Yang H, ILSI Research Foundation: Principles for characterising the potential human health effects from exposure to nanomaterials: elements of a screening strategy. Part Fibre Toxicol 2005, 2:8.
7. Bhattacharya K, Hoffmann E, Schins RF, Prantl EM, Alink GM, Byrne HJ, Kuhlbusch TA, Rahman Q, Wiggers H, Schulz C, Dopp E: Comparison of micro-and nanoscale Fe3+ containing (hematite) particles for their toxicological properties in human lung cells in vitro. Toxicol Sci 2012, 126:173-182.
8. Sadauskas E, Jacobsen NR, Danscher G, Stoltenberg M, Vogel U, Larsen A, Kreyling W, Wallin H: Bio-distribution of gold nanoparticles in mouse lung following intratracheal instillation. Chem Cent J 2009, 3:16.
9. Lee JH, Kim YS, Song KS, Ryu HR, Sung JH, Park HM, Song NW, Shin BS, Marshak D, Ahn K, Lee JE, Yu IJ: Bio-persistence of silver nanoparticles in tissues from Sprague-Dawley rats. Part Fibre Toxicol 2013, 10:36.
10. Lipka J, Semmler-Behnke M, Sperling RA, Wenk A, Takenaka S, Schleh C, Kissel T, Parak WJ, Wolfgang KG: Bio-distribution of PEG-Modified gold nanoparticles following intratracheal instillation and intravenous injection. Biomaterials 2010, 31:6574-6581.
11. Semmler-Behnke M, Kreyling WG, Lipka J, Fertsch S, Wenk A, Takenaka S, Schmid G, Brandau W: Bio-distribution of 1.4-and 18 nm gold particles in rats. Small 2008, 12:2108-2111.
12. Balasubramanian SK, Jittiwat J, Manikandan J, Ong CN, Yu LE, Ong WY: Biodistribution of gold nanoparticles and gene expression changes in the liver and spleen after intravenous administration in rats. Biomaterials 2010, 13:2034-2042.
13. Kermanizadeh A, Brown DM, Hutchison G, Stone V: Engineered nanomaterial impact in the liver following exposure via an intravenous route-the role of polymorphonuclear leukocytes and gene expression in the organ. Nanomedicine Nanotechnol 2013, 4:157.
14. Kermanizadeh A, Chauché C, Balharry D, Brown DM, Kanase N, Boczkowski J, Lanone S, Stone V: The role of Kupffer cells in the hepatic response to silver nanoparticles. Nanotoxicology 2014, 8:149-154.
15. Kermanizadeh A, Gaiser BK, Johnston H, Brown DM, Stone V: Toxicological impact of engineered nanomaterials on the liver-a review. Br J Pharmacol 2014, 171:3980-3987.
16. Kmiec Z: Co-operation of liver cells in health and disease. Adv Anat Embryol Cell Biol 2001, 161:1-151.
17. Gaiser BK, Hirn S, Kermanizadeh A, Kanase N, Fytianos K, Wenk A, Haberl N, Kreyling W, Stone V: Effects of silver nanoparticles on the liver and hepatocytes in vitro. Toxicol Sci 2013, 131:537-547.
18. Godoy P, Hewitt NJ, Albrecht U, Andersen ME, Ansari N, Bhattacharya S, Bode JH, Bolleyn J, Borner C, Bottger J, Braeuning A, Budinsky RA, Burkhardt B, Cameron NR, Camussi G, Cho CS, Choi YJ, Craig Rowlands J, Dahmen U, Damm G, Donato MT, Dong J, Dooley S, Drasdo D, Eakins R, Ferreira KS, Fonsato V, Fraczek J, Gebhardt R, Gibson A, et al: Recent advances in 2D and 3D in vitro Systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signalling and ADME. Arch Toxicol 2014, 87:1315-1530.
19. Teigs G, Lohse AW: Immune tolerance: What is unique about the liver. J Autoimmun 2009, 34:1-6.
20. Kim BS, Park IK, Hoshiba T, Jiang HL, Choi YJ, Akaike Y, Cho CS: Design of artificial extracellular matrices for tissue engineering. Progr Polymer Sci 2011, 36:238-268.
21. Mingoia RT, Nabb DL, Yang CH, Han X: Primary culture of rat hepatocytes in 96 well plates: effects of extracellular matrix configuration on cytochrome P450 enzyme activity and inducibility and its application in vitro cytotoxicity screening. Toxicol In Vitro 2007, 21:165-173.
22. Messner S, Agarkova I, Moritz W, Kelm JM: Multi-cell human liver microtissues for hepatotoxicity testing. Arch Toxicol 2013, 87:209-2313.
23. Kratschmar DV, Messner S, Moritz W, Odermatt A: Characterization of a rat multi-cell type 3D-liver microtissue system. Tissue Sci Eng 2013, 4:2.
24. Kermanizadeh A, Pojana G, Gaiser BK, Birkedal R, Bilanicová D, Wallin H, Jensen KA, Sellergren B, Hutchison GR, Marcomini A, Stone V: In vitro assessment of engineered nanomaterials using C3A cells: cytotoxicity, pro-inflammatory cytokines and function markers. Nanotoxicology 2013, 7:301-313.
25. Puthothu B, Krueger M, Heinze J, Forster J, Heinzmann A: Impact of IL8 and IL8-receptor alpha polymorphisms on the genetics of bronchial asthma and severe RSV infections. Clin Mol Allergy 2006, 4:2-8.
26. Mocellin S, Panelli MC, Wang E, Nagorsen D, Marincola FM: The Dual Role of IL10. Trends Immunol 2004, 24:36-43.
27. Moore KW, Malefyt R, Coffman RL, O'Garra A: Interluekin-10 and the Interluekin-10 Receptor. Annu Rev Immunol 2001, 19:683-765.
28. Guengerich FP: Common and uncommon cytochrome P450 reactions related to metabolism and chemical toxicity. Chem Res Toxicol 2001, 14:611-650.
29. Guengerich FP: Cytochromes P450, drugs and diseases. Mol Interv 2003, 3:194-204.
30. Dong BW, Liang P, Yu XL, Zeng XQ, Wang PJ, Su L, Wang XD, Xin H, Li S: Sonographically guided microwave coagulation treatment of liver Cancer: an experimental and clinical study. Am J Roentgenol 1998, 171:449-454.
31. Kermanizadeh A, Gaiser BK, Ward MB, Stone V: Primary human hepatocytes vs. hepatic cell line-assessing their suitability for in vitro nanotoxicology. Nanotoxicology 2013, 7:1255-1271.
32. Stadnyk AW, Baumann H, Gauldie J: The acute-phase protein response in parasite infection. Nippostrongylus brasiliensis and yrachinella spiralis in the rat. Immunology 1990, 69:588-595.
33. Baffy G: Kupffer cells in non-alcoholic fatty liver disease: the emerging view. J Hepatol 2009, 51:212-223.
34. Bottcher JP, Knolle PA, Stabenow D: Mechanisms balancing tolerance and immunity in the liver. Dig Dis 2011, 29:384-390.
35. Nemeth E, Baird AW, O'Farrelly C: Microanatomy of the liver immune system. Semin Immunopathol 2009, 31:333-343.
36. Fainboim L, Chernavsky A, Paladino N, Flores AC, Arruvito L: Cytokines and chronic liver disease. Cytokine Growth Factor Rev 2007, 18:143-157.
37. Chen C, Zhang P, Hou X, Chai Z: Sub-cellular distribution of Selenium and Se-containing proteins in human liver. Biochim Biophys Acta 1999, 1427:205-215.
38. Diesen DL, Kuo PC: Nitric oxide and redox regulation in the liver: Part I. General considerations and redox biology in hepatitis. J Surg Res 2009, 162:95-109.
39. Sharma V, Singh P, Pandey AK, Dhawan A: Induction of oxidative Stress, DNA damage and apoptosis in mouse liver after sub-acute exposure to zinc oxide nanoparticles. Mutat Res 2012, 745:84-91.
40. Walczk D, Bombelli FB, Monopoli MP, Lynch I, Dawson KA: What the Cell "Sees" in Bionanoscience. J Am Chem Soc 2010, 132:5761-5768.
41. Landsiedel R, Ma-Hock L, Kroll A, Hahn D, Schnekenburger J, Wiench K, Wohlleben W: Testing metal oxide nanomaterials for human safety. Adv Mater 2010, 22:2601-2627.
42. Oberdorster G: Nanotoxicology: in vitro-in vivo dosimetry. Environ Health Perspect 2012, 120:13.
43. Basich BL, Corson NM, Wade-Mercer P, Gelein R, Kennell AJ, Ocerdorster G, Elder A: Equivalent titanium dioxide nanoparticle deposition by intratracheal instillation and whole body inhalation: the effect of dose rate on acute respiratory tract inflammation. Part Fibre Toxicol 2014, 11:5.
44. Gangwal S, Brown JS, Wang A, Houck KA, Dix DJ, Kavlock RJ, Hubal EAC: Informing selection of nanomaterial concentrations for ToxCast in vitro testing based on occupational exposure potential. Environ Health Perspect 2011, 119:1539-1546.
45. Cho WS, Duffin R, Bradley M, Megson IL, MacNee W, Lee JK, Jeong J, Donaldson D: Predictive value of in vitro assays depends on the mechanism of toxicity of metal oxide nanoparticles. Part Fibre Toxicol 2013, 10:55.
46. Oliveira E, Santos HM, Garcia-Padro J, Diniz M, Lorenzo J, Rodriguez-Gonzalez B, Capelo JL, Lodeiro C: Synthesis of functionalized fluorescent silver nanoparticles and their toxicological effects in aquatic environments and HEPG2 cells. Front Chem 2013, 1:29.
47. Wu Y, Zhou Q: Silver nanoparticles cause oxidative damage and histological changes in Medaka (Oryzias Latipes) after 14 days of exposure. Environ Toxicol Chem 2012, 32:165-173.
48. Møller P, Jacobsen NR, Folkmann JK, Danielsen PH, Mikkelsen L, Hemmingsen JG, Vesterdal LK, Forchhammer L, Wallin H, Loft S: Role of oxidative damage in toxicity of particulates. Free Radic Res 2010, 44:1-44.
49. Kermanizadeh A, Gaiser BK, Hutchison GR, Stone V: An in vitro liver model-assessing oxidative stress and genotoxicity following exposure of hepatocytes to a panel of engineered nanoparticles. Part Fibre Toxicol 2012, 9:28.
50. Westerink WMA, Schoonen WGEJ: Cytochrome P450 enzyme levels in HepG2 cells and cryopreserved primary human hepatocytes and their induction in HepG2 cells. Toxicol In Vitro 2007, 21:1581-1591.
51. Villeneuve JP, Pichette V: Cytochrome P450 and the liver diseases. Curr Drug Metab 2004, 5:273-282.
52. Liguori MJ, Blomme EAG, Waring JF: Trovafloxacin induced gene expression changes in liver derived in vitro systems: comparison of primary human hepatocytes to HepG2 cells. Drug Metabol Dispos 2008, 36:223-233.
53. Sahi J, Grepper S, Smith C: Hepatocytes as a tool in drug metabolism, transport and safety evaluations in drug discovery. Curr Drug Discov Tech 2010, 7:188-198.
54. Hansson PK, Asztely AK, Clapham JC, Schreyer SA: Glucose and fatty acid metabolism in McA-RH777 hepatoma cells vs. rat primary hepatocytes: responsiveness to nutrient availability. Biochim Biophys Acta 2004, 1:54-62.
55. Donaldson K, Schinwald A, Murphy F, Cho WS, Duffin R, Tran L, Poland C: The biologically effective dose in inhalation nanotoxicology. Acc Chem Res 2012, 46:723-732.
56. Jacobsen NR, Pojano G, Wallin H, Jensen KA: Nanomaterial dispersion protocol for toxicological studies in ENPRA. Internal ENPRA Project Report. The National Research Centre for the Working Environment 2010, Available on request.
57. Speit G, Schütz P, Bonzheim I, Trenz K, Hoffmann H: Sensitivity of FPG protein towards alkylation damage in the comet assay. Toxicol Lett 2004, 146:151-158.
58. Sidorkina OM, Laval J: Role of lysine-57 in the catalytic activities of Escherichia Coli formamidopyrimidine-DNA glycosylase (Fpg protein). Nucleic Acids Res 1998, 1:5351-5357.